基于miRNAs调控免疫紊乱探讨脓毒症卫、气分证及“病证结合、方证对应”理论指导下凉膈散干预作用机制

Sepsis is the main cause of death due to infection in worldwide.Based on previous researches, under guidance of the theory of combination-disease-with-syndrome and prescriptions-corresponding-to-syndromes,combined with research progress about immune disorder of sepsis of modern medicine,this research is about to take Weifen syndrome and Qifen syndrome as cutting points,launch animal experiments, by ways of multiple techniques of RT-PCR, FCM,ELISA and so on, observe mechanism of immune disorder in Weifen syndrome and Qifen syndrome,besides, observe the regulatory effect of miRNAs, so as to reveal some essence of Weifen syndrome and Qifen syndrome at the genetic level. At the same time, our research is going to treat Weifen syndrome and Qifen syndrome with Liangge San, a clinical effective prescription against early phase of sepsis, combine with in vivo experiments, explain the mechanism of its effects from the point of immune hyperfunction (release of pro- and anti-inflammatory mediators) and immunosuppression (apoptosis of lymphocytes) regulated by miRNAs, expecting to confirm Chinese medicine compound’s advantage of regulating early phase of sepsis.as a whole, then compare Liangge San’s different effects on Weifen syndrome and Qifen syndrome and analyze the mechanism, in order to confirm Liangge San’s superior syndrome and combine sepsis(DISEASE) with Qifen syndrome(SYNDROME), then with Liangge San(PRESCRIPTION), so as to providing evidence for treating sepsis based on syndrome differentiation more effectively, further, for establishing a diagnosis and treatment scheme for sepsis. At the other hand, the research may pour new scientific connotation in theory of combination-disease-with-syndrome and prescriptions-corresponding-to-syndromes.

脓毒症是感染致死的最主要原因。 本项目基于前期研究基础， 在 “病证结合，方证对应”理论指导下，从卫分证、气分证切入，开展动物实验，运用 RT-PCR、FCM、ELISA 等多种技术，观察脓毒症卫分证、气分证免疫紊乱机制miRNAs 的调控作用，在基因水平揭示卫分证、气分证部分证候实质；并以临床治疗早期脓毒症的效验方凉膈散干预，辅以体外细胞实验，从 miRNAs及其靶基因调控的免疫亢进（促炎/抗炎因子释放） 、免疫抑制（淋巴细胞凋亡）角度阐释其作用机制，以明确中药复方对脓毒症免疫紊乱的整体调节优势；并分析凉膈散对卫分证、气分证的不同干预效果及机制，明确凉膈散的优势证候，以期将脓毒症( “病” )-气分证( “证”)-凉膈散( “方” )有机结合，为临床更有效辨证论治脓毒症、进而建立脓毒症中医辨证论治诊疗方案提供实验依据，同时为“病证结合，方证对应”注入新的科学内涵。

脓毒症是世界范围内感染致死的最主要原因。 本项目在前期研究基础上， 在 “病证结合，方证对应”理论指导下，结合有关脓毒症免疫紊乱机制研究进展，从卫分证、气分证切入，开展动物实验，运用 RT-PCR、FCM、ELISA 等多种技术，观察脓毒症卫分证、气分证免疫紊乱机制miRNAs 的调控作用，在基因水平揭示卫分证、气分证部分证候实质；同时以临床治疗早期脓毒症的效验方凉膈散干预，辅以体外细胞实验，从 miRNAs及其靶基因调控的免疫亢进（促炎/抗炎因子释放） 、免疫抑制（淋巴细胞凋亡）角度阐释其作用机制，以明确中药复方对脓毒症免疫紊乱的整体调节优势；并分析凉膈散对卫分证、气分证的不同干预效果及机制，明确凉膈散的优势证候，以期将脓毒症（ “病” ）—气分证（ “证” ）—凉膈散（ “方” ）有机结合，为临床更有效辨证论治脓毒症、进而建立脓毒症中医辨证论治诊疗方案提供实验依据。